Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations
Retrieved on:
Monday, November 20, 2023
BASEL, Switzerland, Nov. 20, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Boehringer Ingelheim, one of the largest producers of biopharmaceuticals in the world, has expanded usage of the Genedata platform to include the Drug Metabolism and Pharmacokinetics (DMPK) group in the US. The DMPK US operations use Genedata Biologics® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.
Key Points:
- The DMPK US operations use Genedata Biologics ® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.
- We have been using Genedata Biologics across our early biologics discovery operations for many years and are very excited to onboard the US-DMPK group as this is a major step towards having complete end-to-end digital tracking of all BI's therapeutic candidates.
- "After an initial evaluation, the DMPK group was eager to get onto the Genedata Biologics platform and take advantage of having all information pertaining to critical reagents in one place.
- One of the strengths of Genedata Biologics is the platform's ability to integrate with Boehringer Ingelheim's laboratory instruments, sample management systems, and corporate IT infrastructure.